, 1996

(), .
, ,
,
.
, , ,
.

- , -
()



(), ,
().

.

, , ,

. ,
,
, ,
. ,
, .
,
, ,
,
. ,
,
, .

,
. ,

. ,

.
.
.
,
, , ,
, ,
.
- ,

1. ...1
2. ..4
3. ....11
4. 13
5. , .18
6. ..22
7. ..24
8. VIII IX30
9. ..34
10. ..40
11. :
..43
12. ..49
13. , ..55
14. ..61
15. ..63
16. .64
17. ..66
1 ..69
2 .75

1.

.
. ,
, ,
. , ,
, , .
,
VIII. ,
IX ( ,
), , .
, ,
-.
,
, .. .
, ,
VIII, , ,
, ,
.
1 10 000 . (
VIII 1%) 1 16 000. ,
. ,
350 000 ,
70 000.
, ,
,
, ,
.
, , , ,
, ,

,
;

,

.


(), .
. ,
20%
.
, ,
.
,
.
. ,
,
, 1994,
65.

.4
2.
.
VIII IX .
,
. ,
1% 1, .
1 5% , 5%
. VIII IX 50
200% (5-20 /) 100% .
VIII IX .

, ;
.

.
.
,

. , ,

1 (/)
6


.
,
, ,

.5
.
.
, ,
. (,
),
. ( ,
, )
, , ,
, .
.
35 , .
, ,
. , .

, .
, . ,
, ,
.
,
- . ,
,
, .
,
.
.6
, , :

, ,
;

.
7


.

,
. ,
, . ,
,
. , , ,
,
, .
VIII IX .
.
. :

, , 1 2;

,

;

.7

,
.

VIII IX
,
. - , ,
.

-
. , , ,
, , , , ,
. , ,
, 50 , 35 000 VIII
, (35 1000
VIII, ). ,
(. .39).

 , ,
, ,
.
.
1.
1.

- ,

()

, ,
. ,


.
. IX ,
. , , IX
, VIII.
VIII ,
, , , , ,
.

.
, ,

.
, .
,
, , ,
, , .
- . ,
,
- , ,
.
, ,
, ,
.

() .
,
( ).
( ,
) ,
, . ,
, .
,

. , ,
.
,
, , ,
. , , ,
.
,
, - .
,
, , , .

10

.11
2.
,
. , .
, ,
, .
,
.
, - .
. 2.
, ,
. ,
, ,
(
).

,
.
VIII,
(DDAVP). VIII
.
, IX.


,
. .
, .

, .

.
,
.

11

.13
3.
.


.
.
/
. ,
, ,
,

12

.14


...:
:
:
:
:


1.
1.1 1

1.2 1

,
,

1.3

( > 5 ) 1

( < 5 ) 2
1.4

2
1.5

,
?

1
2

1.6 :

13

2.
2.1 1 2

, ,

2.2 :

,
, ?

2.3 :

3.
3.1 1

3.2 :
3.3 :
.15
4.
4.1 1 2

-
.

4.2

4.3 :

5. /
5.1 1 2
5.2 :

14

6. ( , , )
6.1 1

,
,


(),

6.2 1

2 -.

.

,
7.
7.1
7.2

1 2
1
2

7.3 1 2
8.
8.1

1 2

8.2

:
1
2

15

8.3

?
1

8.4

9.
9.1

9.2

9.3

1
2

9.4

1
2

10.
10.1 1 2
10.2 ,
:
/
11.1

1 2

11.2

1 / 2

11.3

1 2

11.4

16

 , ():
11.5

11.6

1
2

11.7

12.1

12.2

, .
,
.

13.1

13.2

13.3

14.1
14.2

17

15.1 ( )
15.2
15.3
15.4
15.5

5.

,
, ,
, , .. ,
.

.
,
.
,
(Peake ., 1995).
,

.
.
:

18

( )

( )

VIII

IX

, ()
.
.

VIII IX, ..
(

, ,
II (), V, VII, X, XI
XIII

19


,
:

VIII
IX

:
:

XII
(, )
2
, , - ,
, ,
, , ..
.
.
,
, ,
, , , ( 1 2). ,
, .
-

,
.
, .

, . t - 20 (.
2).

20


, ,
, ,
.
,
.
. ,
.
,
.
6.
, ,

. ,
.
,
,
. (
VIII) ,
VIII,
(1--8-- ; ; .
). ,
. , , IX,
.
, ,
, .
,
IX, .
, ,
.
, ,
,
,
.
,
.
21

 ,
, .
, .
7.
,
, VIII IX.
VIII :



()

VIII ()
VIII ()
VIII ( )
VIII.
, VIII .
IX :



,
()
( ) ,
IX ()
VIII ( )

IX. , ,
. .

22

:
VIII (Hyate ) ,
VIII.
4
VIII, .
. , VIII,
, .
IX
: (PCCs), II, VII, IX X

: , IX
PCCs
,
, , .
IX
.

, ,
, ,
. ,
. ,
,
,
, (),
, VIII IX
,
, .
,
,
. ,
.

23


,
. ,
,
, , .

,
,
, . 80-
-

. :

, ,
,

, ,

, ,
, .
(
),
(,
-).
,
,
. , ,
, ,
.

24


: ,
,
,
.
:

.
, , ,
. , 80 72

, . -
.
, ,

. ,
. , ,
, . , ,
, ,
, 60 10 ,
.

,
. ,
,
. , , ,
, . 7
35 000
VIII .

25

 . , ,
(. .30) ,
100 000 VIII .
, ,
.

,
, ,
.
,
,
(. .49). ,
,
, , ,
.
.30
8. VIII IX
,
VIII IX.
. ,
100 . , .
, , 50% , VIII,
.
.
, , ,
. .
VIII
.
(B.U.). < 10
B.U. ????? 10-20%
> 10 B.U., .
VIII ,
VIII.
VIII, .
26

VIII,

.

37. (Kasper
.), 2 .


1994 ., 1995 .

VIII
25-50 /. ,
.
VIII, ,
, 200 / ( ).
:
-

VIII

VIII (Hyate C, Speywood Laboratories, )

(FEIBA,
Immuno, ; Autoplex, Baxter, )

VII (Novo Nordisk, ).

27


. VIII
VIII ,
. , ,
, VII
.
;
.
,
VII.
.
.
, .
, ,
. ,
.

,
. , ,
.


.
.
9.
.
. . 1
16 000. , ,
.
. .
, -
, .
, ,

.
28

. .
, ,
. ,
, .
. , ,
.
(), .
,
??????
. , ,
. .
, ,
.
. ,
. ,
.
\ ,
. ,
,
.
.
, , ,
.
,
.
. ,
, .
, ,
, = ,
, .
,
. , ,
, .
, , ,
, , .

29

 , , ,
, , .
, ..
. ,
.
, .
. ,
, \
,
.

:

,
, ,
.

???? ,
.

,
.
:

, , ,
, ,
, ;

,
, ,
, , , ,

; ,
.

30

 ,
, ,
, , ,
,
.

, ,

. ,
.

, ,
.
, (, , ).

. , ,
,
, ,
.

.
,
, :

.40
10.
.

, .
, , .

31

 ,
, ,
.
, ,
.
, ,
,
, , ,
.
.
:
,
,
-

:
,

, , , 1 2,

,

.
,
, ,
.
. ,
, .
,
.
_____________________________

32

 : -
. .
, ,
, , 1988 .
. ,
, , . ,
, , , ,
, ,
. 1989 .,
, ,
.
1988 . 1989 . ,
. ,
.
. .
, 4- ., , 1995

. 42.
: , , , , ,
, , , , , ,
, , , , , , .

11.
, , ,
. ,
, .
, , ,
,
.
,
. VIII IX -.
, (XY), (XX) ,
-,
.
33

12

X XX XY XY

34

13

23

1 42 4

= , .
, - ,
.

12

34

13

23

XX XY XY
14

24

1 - .
.
, ,
. - .

. ,
.

, :

( )

34

 , , ..
. ,
, ,
,
.

, :

, ,
,
1992 . (. ).
,
, (Lakich ., 1993) (Eikenboom, Reitsma
Briet, 1995). ,
22 -,
50% . ,
,
, IX, .

, ,
, ,
.
-.
,
,
, .

,
, .. , .
, ,
VIII IX, ,

35

 .
, VIII IX,
-. ,
VIII IX, .
,
VIII, IX, .

, , ,
. , 16-20
, . ,
.
, ,
, ,
. , 3%
.
. ,
.
, .
:

(CVS)

. , .

VIII IX

, , .
.

36


,
sodium citrate. VIII IX
, ,
. ,
, VIII
IX , ,
, ,
.
,
.

12.

, . ,
().
, , 40
.
, ,
. ,

, ,
.
, .
,
, , , ,

. ,
,
.

.
1993 . ,
.
.
37


,
, . , , , ,
, , ,
.
,
, ,
.
,

.
,
.
,
,
:

,
. , ,
;

,
,

;

,
,
.

38

().

,

.
. ,
I.

,

.

II.

,
.

.

III.

IV.

.
.

V.

, ,
,
.

VI.

;
.
,
, ,
.

VII.

VIII.

IX.

,
, .
39

X.

XI.

, .

XII.

, , ,
, ( ), , ,
,
.

XIII.

, ,
.
,
,
?????. , ,

.

XIV.

,
, ,
,
.

XV.

-
, ,
.

. ,
,
, I IX.
13.
.
, , , ,

. ,
, .
,

, .

40

,
.
.

, - .
, ,
.
:
1.
( returns , )
) :

.

.

, .
.
) :

, ,
,
.

VIII IX,
, ,

41

 .
.

, , ,
( )

, ,
.
)

42

)
(
20), ,
.
.
,
.
- ,
.

1. ?
2. :

,
?
3. :
( )
(
).
4. ,
?
)
)
) -
)
)
)
) -
)
)

43

5. , , ,

)
)
)
) ( )
)
6. ?

. 61
14.
1. . ,
.
, ,

.
2. ,
, , .
,
, .
3.
.
.

.
4. .

, .
5.
-
.
6. .

.
,
44

, ,
.
7.
, :
1310 Green Avenue, Suite 500, Montreal, Quebec, Canada H3Z 2B2.
Tel: (514) 933 7944
Fax: (514) 933 8916
e-mail: wfh@wfh.org
Web-site: http//www.wfh.org
15.

, .
- :
, - , , , -
, - , - , - , -
, - , , , ,
, ,
.

. - -
, . . . -
, - -
, .
() (, )
.

.

45

.64
16.
Eikenboom JC, Reitsma PH and Briet E. The inheritance and molecular genetics of von Willebrand's
disease. Haemophilia 1, 77-90, 1995.
Kasper CK, Aledort LM, and Counts RB. A more uniform measurement of factor VIII inhibitors.
Thrombosis et Diathesis Haemorrhagica, 34: 869-72, 1975.
Kasper CK, Mannucci PM, Boulyjenkov V, Brettler DB, Chuansumrit A, Heijnen L, Israngkura P, Kernoff
, Peake I, Rickard KA, Schulman S, and Smit Sibinga CT. Haemophilia in the 1990s: Principles
of management and improved access to care. Seminars in Thrombosis and Hemostasis 18 (1): 1-10, 1992.
Kessler CM, Gellert GA, Mariani G, Patrick DF and Levine PH. Catalyzing global access to
hemophilia care. Thrombosis and Haemostasis, 73, 896-7, 1995.
Lakich D, Kazazian H, Antonarakis S, and Gitschier J. Inversions disrupting the factor VIII gene are a
common cause of severe haemophilia A. Nature Genetics 5, 236-41, 1993.
Mariani G, Mannucci PM and Cattaneo M. Desmopressin in bleeding disorders. NATO ASI Series A
242, Plenum Press, 1995.
Peake I, Seligsohn U, Gitel S, Kitchen S and Zivelin A. The laboratory diagnosis of haemophilia:
Recommendations by the Laboratory Activities Committee of the World Federation of Hemophilia.
Haemophilia 1, 159-64, 1995.
Recommendations on choice of therapeutic products for the treatment of patients with haemophilia A,
haemophilia and von Willebrand's disease. UK Regional Haemophilia Centre Directors Committee. Blood
Coagulation and Fibrinolysis 3, 205-14, 1992.
Report of a joint WHO/WFH meeting on the control of haemophilia: carrier detection and prenatal
diagnosis. Blood Coagulation and Fibrinolysis 4, 313-44, 1993.
The control and management of haemophilia.

Proceedings of a Joint WHO/WFH Meeting, March

1994. Haemophilia 1, Supplement 1, 1995.

46

: .

1990

Report of a Joint WHO/WFH Meeting on the Possibilities for the P revention and
Control of Haemophilia (WHO/HDP/ WFH/90.3).

1992

Educational Materials on Haemophilia for Families (WHO/HDP/HAEM/EMT/92.1).

1992

Educational

Materials

on

Haemophilia

for

Health

Care

Professionals

(WHO/HDP/HAEM/EMT/92.2).
1992

Report of a Joint WHO/WFH Meeting on the Control of Haemophilia: Carrier Detection

and Prenatal Diagnosis (WHO/HDP/WFH/92.4).

1994

Report

of

Haemophilia:

Joint

WHO/WFH

Modern

Meeting

Treatment

on

the
of

Control

of

Haemophilia

(WHO/HDP/WFH/94.6).

17.

,

.

,
.
( ).

,

.
VIII, .
IX.

VIII

() ,

. VIII
.

IX

() ,
.

47

 .
II (), VII, IX X
" ",
.
() ,

40.
,
.
( ),
.

. ,
VIII IX.

VIII

IX (
)

,


.

.
,

.

(, , ,
).

.
48

, ,
-

.


.

, VIII.
,
( ),

.

. ,
VIII IX
.

VIII

VIII
.

.

.
,


.

.
VIII.
IX
.

, ,

49

 .

.

.
VIII.

1

,
84 .
,
.
, ,
.
23 (IHTC) ,
.
,
. ,
, ,
,

.
:

1310 Green Avenue

Tel: + 1 514 933 7944

Suite 500

Fax: + 1 514 933 8916

Montreal

e-mail: wfh@wfh.org

Quebec

Web site: http//www.wfh.org

Canada H3Z 2B2

. :
,
,
-,
50

 , ,
,
,
,
,
-,
,
,
-,
,
,
,
--,
, ,
,
,
-,
,
,
, ,

:

51

5 .
1.
,
.
2. ,
,
.
3. ,
, , ,
,
.
4.
, .
5.
, .

52


.
, .
, ,
. :
-

,

: , ,
,
.

,
.
-,
, ..
.

(CODEN HAEMF4
ISSN 1351-8216).
Blackwell Science Ltd
Osney Mead, Oxford, OX2 0EL, UK
Tel: +44 1865 206206
Fax: +44 1865 71205

, .
-

,
, .

,
-, ,
.

,
, ,
.

,
.

53

.
1969
.
,
. .
.

54